Peter Attia MD | What is the future of obesity treatment? @PeterAttiaMD | Uploaded August 2024 | Updated October 2024, 6 hours ago.
#314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards
In the full episode, we discuss:
- The complex relationship between nutrition, body weight, and body composition
- The slow progress in addressing obesity and public health despite substantial effort and investment
- The very limited success of public health initiatives in curbing obesity
- The evolving landscape of obesity research: public health initiatives and the impact of pharmacological success
- Rethinking obesity solutions: the need for a paradigm shiftt
- Understanding environmental triggers and embracing a balanced approach to addressing obesity that includes both pharmacological treatments and realistic lifestyle changes
- The need for higher standards in obesity research
- The rapid success of GLP-1 receptor agonists for weight loss: a discussion on the societal impact and controversy of their growing usage
- The ethical and practical considerations of obesity drugs: risks, benefits, and motivations for usage
- The use of GLP-1 agonists by athletes as performance enhancers
- Unanswered questions about protein intake and health
- Future research needed to understand basic questions around protein intake
- David’s weekly newsletter: “Obesity and Energetics Offerings”
- More
--------
About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.
Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan.
Learn more: peterattiamd.com
Connect with Peter on:
Facebook: bit.ly/PeterAttiaMDFB
Twitter: bit.ly/PeterAttiaMDTW
Instagram: bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: bit.ly/TheDriveApplePodcasts
Overcast: bit.ly/TheDriveOvercast
Spotify: bit.ly/TheDriveSpotify
Google Podcasts: bit.ly/TheDriveGoogle
Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: peterattiamd.com/terms-of-use
#314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards
In the full episode, we discuss:
- The complex relationship between nutrition, body weight, and body composition
- The slow progress in addressing obesity and public health despite substantial effort and investment
- The very limited success of public health initiatives in curbing obesity
- The evolving landscape of obesity research: public health initiatives and the impact of pharmacological success
- Rethinking obesity solutions: the need for a paradigm shiftt
- Understanding environmental triggers and embracing a balanced approach to addressing obesity that includes both pharmacological treatments and realistic lifestyle changes
- The need for higher standards in obesity research
- The rapid success of GLP-1 receptor agonists for weight loss: a discussion on the societal impact and controversy of their growing usage
- The ethical and practical considerations of obesity drugs: risks, benefits, and motivations for usage
- The use of GLP-1 agonists by athletes as performance enhancers
- Unanswered questions about protein intake and health
- Future research needed to understand basic questions around protein intake
- David’s weekly newsletter: “Obesity and Energetics Offerings”
- More
--------
About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.
Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan.
Learn more: peterattiamd.com
Connect with Peter on:
Facebook: bit.ly/PeterAttiaMDFB
Twitter: bit.ly/PeterAttiaMDTW
Instagram: bit.ly/PeterAttiaMDIG
Subscribe to The Drive:
Apple Podcast: bit.ly/TheDriveApplePodcasts
Overcast: bit.ly/TheDriveOvercast
Spotify: bit.ly/TheDriveSpotify
Google Podcasts: bit.ly/TheDriveGoogle
Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: peterattiamd.com/terms-of-use
